Genomic interaction between ER and HMGB2 identifies DDX18 as a novel driver of endocrine resistance in breast cancer cells

Oncogene

Volumn 34, Issue 29, 2015, Pages 3871-3880

  Redmond, A M ^a,b   Byrne, C ^a   Bane, F T ^a   Brown, G D ^b   Tibbitts, P ^a   O'Brien, K ^a   Hill, A D K ^a   Carroll, J S ^b   Young, L S ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DEAD BOX PROTEIN; DEAD BOX PROTEIN 18; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTRADIOL; ESTROGEN RECEPTOR; HIGH MOBILITY GROUP B2 PROTEIN; MESSENGER RNA; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; STEROID RECEPTOR COACTIVATOR 1; TAMOXIFEN; UNCLASSIFIED DRUG; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DDX18 PROTEIN, HUMAN; PROTEIN BINDING;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER HORMONE THERAPY; CANCER SURVIVAL; CELL CYCLE REGULATION; CELL GROWTH; CELL PROLIFERATION; COHORT ANALYSIS; COMPLEX FORMATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENE INTERACTION; GENETIC ASSOCIATION; GENOMICS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MCF 7 CELL LINE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN CROSS LINKING; SURVIVAL TIME; TRANSCRIPTION INITIATION SITE; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; BREAST NEOPLASMS; DNA MICROARRAY; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DEAD-BOX RNA HELICASES; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HMGB2 PROTEIN; HUMANS; KAPLAN-MEIER ESTIMATE; MCF-7 CELLS; MICE, INBRED BALB C; MICE, SCID; NUCLEAR RECEPTOR COACTIVATOR 1; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; RECEPTORS, ESTROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TAMOXIFEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84937516441     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.323     Document Type: Article

References (44)

1. Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011; 378: 771-784.
2. Onate SA, Tsai SY, Tsai MJ, O'Malley BW. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 1995; 270: 1354-1357.
3. Redmond AM, Bane FT, Stafford AT, McIlroy M, Dillon MF, Crotty TB et al. Coassociation of estrogen receptor and p160 proteins predicts resistance to endocrine treatment; SRC-1 is an independent predictor of breast cancer recurrence. Clin Cancer Res 2009; 15: 2098-2106.
4. Qin L, Liu Z, Chen H, Xu J. The steroid receptor coactivator-1 regulates twist expression and promotes breast cancer metastasis. Cancer Res 2009; 69: 3819-3827.
5. McBryan J, Theissen SM, Byrne C, Hughes E, Cocchiglia S, Sande S et al. Metastatic progression with resistance to aromatase inhibitors is driven by the steroid receptor coactivator SRC-1. Cancer Res 2012; 72: 548-559.
6. Walsh CA, Bolger JC, Byrne C, Cocchiglia S, Hao Y, Fagan A et al. Global gene repression by the steroid receptor coactivator SRC-1 promotes oncogenesis. Cancer Res 2014; 74: 2533-2544.
7. Stros M. HMGB proteins: interactions with DNA and chromatin. Biochim Biophys Acta 2010; 1799: 101-113.
8. Melvin VS, Harrell C, Adelman JS, Kraus WL, Churchill M, Edwards DP. The role of the C-terminal extension (CTE) of the estrogen receptor alpha and beta DNA binding domain in DNA binding and interaction with HMGB. J Biol Chem 2004; 279: 14763-14771.
9. Zappavigna V, Falciola L, Helmer-Citterich M, Mavilio F, Bianchi ME. HMG1 interacts with HOX proteins and enhances their DNA binding and transcriptional activation. EMBO J 1996; 15: 4981-4991.
10. Tremethick DJ, Molloy PL. High mobility group proteins 1 and 2 stimulate transcription in vitro by RNA polymerases II and III. J Biol Chem 1986; 261: 6986-6992.
11. Laurent B, Randrianarison-Huetz V, Marechal V, Mayeux P, Dusanter-Fourt I, Dumenil D. High-mobility group protein HMGB2 regulates human erythroid differentiation through trans-activation of GFI1B transcription. Blood 2010; 115: 687-695.
12. Wang W, Jiang H, Zhu H, Zhang H, Gong J, Zhang L et al. Overexpression of high mobility group box 1 and 2 is associated with the progression and angiogenesis of human bladder carcinoma. Oncol Lett 2013; 5: 884-888.
13. Boonyaratanakornkit V, Melvin V, Prendergast P, Altmann M, Ronfani L, Bianchi ME et al. High-mobility group chromatin proteins 1 and 2 functionally interact with steroid hormone receptors to enhance their DNA binding in vitro and transcriptional activity in mammalian cells. Mol Cell Biol 1998; 18: 4471-4487.
14. Jolma A, Yan J, Whitington T, Toivonen J, Nitta KR, Rastas P et al. DNA-binding specificities of human transcription factors. Cell 2013; 152: 327-339.
15. McCartan D, Bolger JC, Fagan A, Byrne C, Hao Y, Qin L et al. Global characterization of the SRC-1 transcriptome identifies ADAM22 as an ER-independent mediator of endocrine-resistant breast cancer. Cancer Res 2012; 72: 220-229.
16. Grandori C, Mac J, Siebelt F, Ayer DE, Eisenman RN. Myc-Max heterodimers activate a DEAD box gene and interact with multiple E box-related sites in vivo. EMBO J 1996; 15: 4344-4357.
17. Payne EM, Bolli N, Rhodes J, Abdel-Wahab OI, Levine R, Hedvat CV et al. Ddx18 is essential for cell-cycle progression in zebrafish hematopoietic cells and is mutated in human AML. Blood 2011; 118: 903-915.
18. Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat 2010; 123: 725-731.
19. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009; 9: 631-643.
20. Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM et al. FOXA1 expression in breast cancer-correlation with luminal subtype A and survival. Clin Cancer Res 2007; 13: 4415-4421.
21. Hisamatsu Y, Tokunaga E, Yamashita N, Akiyoshi S, Okada S, Nakashima Y et al. Impact of FOXA1 expression on the prognosis of patients with hormone receptorpositive breast cancer. Ann Surg Oncol 2012; 19: 1145-1152.
22. Ross-Innes CS, Stark R, Teschendorff AE, Holmes KA, Ali HR, Dunning MJ et al. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 2012; 481: 389-393.
23. Shiota M, Izumi H, Miyamoto N, Onitsuka T, Kashiwagi E, Kidani A et al. Ets regulates peroxiredoxin1 and 5 expressions through their interaction with the high-mobility group protein B1. Cancer Sci 2008; 99: 1950-1959.
24. Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, Eeckhoute J et al. Genome-wide analysis of estrogen receptor binding sites. Nat Genet 2006; 38: 1289-1297.
25. de Leeuw R, Flach K, Bentin Toaldo C, Alexi X, Canisius S, Neefjes J et al. PKA phosphorylation redirects ERalpha to promoters of a unique gene set to induce tamoxifen resistance. Oncogene 2013; 32: 3543-3551.
26. Al-azawi D, Ilroy MM, Kelly G, Redmond AM, Bane FT, Cocchiglia S et al. Ets-2 and p160 proteins collaborate to regulate c-Myc in endocrine resistant breast cancer. Oncogene 2008; 27: 3021-3031.
27. Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S et al. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 2008; 68: 826-833.
28. Wortham NC, Ahamed E, Nicol SM, Thomas RS, Periyasamy M, Jiang J et al. The DEAD-box protein p72 regulates ERalpha-/oestrogen-dependent transcription and cell growth, and is associated with improved survival in ERalpha-positive breast cancer. Oncogene 2009; 28: 4053-4064.
29. Limer JL, Parkes AT, Speirs V. Differential response to phytoestrogens in endocrine sensitive and resistant breast cancer cells in vitro. Int J Cancer 2006; 119: 515-521.
30. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006; 10: 515-527.
31. Dillon MF, Stafford AT, Kelly G, Redmond AM, McIlroy M, Crotty TB et al. Cyclooxygenase-2 predicts adverse effects of tamoxifen: a possible mechanism of role for nuclear HER2 in breast cancer patients. Endocr Relat Cancer 2008; 15: 745-753.
32. Schmidt D, Wilson MD, Spyrou C, Brown GD, Hadfield J, Odom DT. ChIP-seq: using high-throughput sequencing to discover protein-DNA interactions. Methods 2009; 48: 240-248.
33. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009; 25: 1754-1760.
34. Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE et al. Modelbased analysis of ChIP-Seq (MACS). Genome Biol 2008; 9: R137.
35. Kharchenko PV, Tolstorukov MY, Park PJ. Design and analysis of ChIP-seq experiments for DNA-binding proteins. Nat Biotechnol 2008; 26: 1351-1359.
36. Li Q, Brown JB, Huang H, Bickel PJ. Measuring reproducibility of high-throughput experiments. Ann Appl Stat 5: 1752-1779.
37. Liu T, Ortiz JA, Taing L, Meyer CA, Lee B, Zhang Y et al. Cistrome: an integrative platform for transcriptional regulation studies. Genome Biol 2011; 12: R83.
38. McLean CY, Bristor D, Hiller M, Clarke SL, Schaar BT, Lowe CB et al. GREAT improves functional interpretation of cis-regulatory regions. Nat Biotechnol 2010; 28: 495-501.
39. Zhang Z, Chang CW, Goh WL, Sung WK, Cheung E. CENTDIST: discovery of co-associated factors by motif distribution. Nucleic Acids Res 2011; 39: W391-W399.
40. Cairns JM, Dunning MJ, Ritchie ME, Russell R, Lynch AG. BASH: a tool for managing Bead Array spatial artefacts. Bioinformatics 2008; 24: 2921-2922.
41. Dunning MJ, Smith ML, Ritchie ME, Tavare S. beadarray: R classes and methods for Illumina bead-based data. Bioinformatics 2007; 23: 2183-2184.
42. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004; 5: R80.
43. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol: 2004; 3; Article 3.
44. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc 1995; 57: 289-300.